---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-133348"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T02:34:17.193376+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Catalyst Pharma appoints Dr. William Andrews as CMO; Dr. Ingenito retires

## Summary
- Gary Ingenito retired as Chief Medical and Regulatory Officer effective June 1, 2025; no disagreement with management.
- William Andrews appointed as new Chief Medical Officer effective June 2, 2025, reporting to CEO Richard Daly.
- Andrews brings 24 years of biopharma experience, including CMO roles at Flexion, Akcea, and Acer Therapeutics.
- Ingenito will serve as a consultant to assist with the transition.

## SEC filing metadata
- accession: 0001193125-25-133348
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312525133348/0001193125-25-133348-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312525133348/d17589d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-133348
- JSON: https://secwatch.observer/filing/0001193125-25-133348.json
- Plain text: https://secwatch.observer/filing/0001193125-25-133348.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.